Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004522165 | SCV005027316 | uncertain significance | Cardiovascular phenotype | 2022-11-10 | criteria provided, single submitter | clinical testing | The p.A52G variant (also known as c.155C>G), located in coding exon 3 of the TRPM4 gene, results from a C to G substitution at nucleotide position 155. The alanine at codon 52 is replaced by glycine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV005059469 | SCV005717269 | uncertain significance | Progressive familial heart block type IB | 2024-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 52 of the TRPM4 protein (p.Ala52Gly). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with TRPM4-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |